Homocysteine and tissue factor pathway inhibitor levels in patients with Fabry&apos;s disease by Fedi, Sandra et al.
6 Mariani MA, Gu YJ, Boonstra PW, Grandjean JG, van Oeveren W,
Ebels T. Procoagulant activity after off-pump coronary operation: is
the current anticoagulation adequate? Ann Thorac Surg 1999; 67:
1370–5.
7 Murkin JM, Newman SP, Stump DA, Blumenthal JA. Statement of
consensus on assessment of neurobehavioral outcomes after cardiac
surgery. Ann Thorac Surg 1995; 59: 1289–95.
8 Stump DA. Selection and clinical significance of neuropsychologic
tests. Ann Thorac Surg 1995; 59: 1340–4.
9 Kim KB, Lim C, Lee C, Chae IH, Oh BH, Lee MM, Park YB. Off-
pump coronary artery bypass may decrease the patency of saphenous
vein grafts. Ann Thorac Surg 2001; 72: S1033–7.
10 Nierich AP, Diephuis J, Jansen EW, Borst C, Knape JT. Heart dis-
placement during off-pump CABG: how well is it tolerated? Ann
Thorac Surg 2000; 70: 466–472.
11 Kapetanakis EI, Stamou SC, Dullum MK, Hill PC, Haile E, Boyce
SW, Bafi AS, Petro KR, Corso PJ. The impact of aortic manipulation
on neurologic outcomes after coronary artery bypass surgery: a risk-
adjusted study. Ann Thorac Surg 2004; 78: 1564–71.
12 van Dijk D, Moons KG, Keizer AM, Jansen EW, Hijman R, Die-
phuis JC, Borst C, de Jaegere PP, Grobbee DE, Kalkman CJ.
Association between early and three month cognitive outcome after
off-pump and on-pump coronary bypass surgery.Heart 2004; 90: 431–
4.
Homocysteine and tissue factor pathway inhibitor levels
in patients with Fabry’s disease
S . FED I , * F . GENS IN I , A. M. GORI ,* R . ABBATE* and W. BORS IN I
*Department of Medical and Surgical Critical Care, Thrombosis Center, Azienda Ospedaliero-Universitaria Careggi, University of Florence,
Florence, Italy; Department of Clinical Pathology, Genetic Unit, University of Florence, Italy; and Department of Neurological Sciences,
University of Florence, Italy
To cite this article: Fedi S, Gensini F, Gori AM, Abbate R, Borsini W. Homocysteine and tissue factor pathway inhibitor levels in patients with
Fabry’s disease. J Thromb Haemost 2005; 3: 2117–9.
Cerebrovascular disorders are a frequent clinical manifestation
of Fabry’s disease, a rare inborn X-linked (locus Xq22)
recessive deficiency of the lysosomal enzyme alpha-galactosi-
dase A. The enzymatic defect results in progressive accumu-
lation of neutral glycosphingolipids in the lysosomes of
vascular endothelial and other cells throughout the body [1].
The incidence of classical disease has been estimated to be
about 1:40000 and clinical features include involvement of
heart, kidney, skin, nervous system, and the eye. Cerebrovas-
cular manifestations consist of large-vessel ectasia, large-vessel
occlusive disease, and small-vessel occlusive disease [2].
The occurrence of clinical manifestations shows phenotypic
variance not only associated to different genetic mutations, but
also within different members of affected families [2]. In the
general population, increased susceptibility to cerebrovascular
ischemic events has been described in relation to prothrombotic
risk factors [3].
Aim of this study was to evaluate the possible role of
prothrombotic risk factors in the clinical presentation of
Fabry’s disease.
We investigated three unrelated Italian families for a total of
nine Fabry patients (four hemizygotes and five heterozygotes,
age ranges 21–55 years) compared with 27 Italian control
subjects (12 males and 15 females; age ranges 21–55 years).
Four of nine Fabry patients (two hemizygotes and two
heterozygotes) had recurrent strokes and one of them suffers
also from Parkinson symptoms. Magnetic resonance imaging
was abnormal in all the patients and showed lacunar infarc-
tions in the periventricular white matter, basal ganglia and
pons [4]. The four patients with cerebrovascular complications
did not present cardiovascular risk factors (e.g. smoking,
dyslipidemia, diabetes, hypertension, cardiopathy, coagulapa-
thies and vasculitis).
Citrated plasma for protein C (PC) activity (DADE-
Behring, Dudingen, France), protein S (PS) activity (Instru-
mentation Laboratory, Milan, Italy), lipoprotein(a) [Lp(a)],
tissue factor (TF) and tissue factor pathway inhibitor (TFPI)
(TintElize Lp(a), Biopool, Umea, Sweden; IMUBIND Tissue
Factor ELISA Kit; IMUBIND Total TFPI ELISA Kit,
American Diagnostica Inc, Greenwich, CT, USA) were
collected and stored at )80 C. Anticardiolipin antibodies
(aCL) IgG/IgM and anti-Beta2-Glycoprotein I (anti-Beta2-
GPI) IgG/IgM (aCL: First Cardiolipin, Eurospital, Trieste,
Italy; anti-Beta2-GPI: Arnika, Milan, Italy) were detected in
serum samples. Homocysteine (Hcy) levels were detected in
EDTA samples by the FPIA method (IMX Abbot Laborat-
ories, Abbott Park, IL, USA). Factor V G1691A, Factor II
G20210A andMTHFRC677T polymorphisms were identified
as previously described [5–7].
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The non-parametric Mann–Whitney U-test for unpaired
data was used for comparisons between single groups. For
genetic analysis, Hardy–Weinberg equilibrium was assessed
using v2analysis.
No patient showed alterations of blood coagulation inhib-
itors, Lp(a) and the presence of antiphospholipid antibodies
and prothrombotic mutations (data not shown). Homocysteine
median value was higher in patients than in controls [11
(6.5–25.6) lmol L)1 vs. 8.8 (4.8–13.8) lmol L)1, P ¼ 0.005]
(Fig. 1A). Hyperhcy (above the 95th percentile cut-off of the
control population;M ¼ 15.5 lmol L)1, F ¼ 12.5 lmol L)1)
was found in the 4/4 patients with cerebrovascular disease.
Median folic acid and vitamin B6 values were lower in patients
than in controls [7.9 (3.2–18.8) nmol L)1 and 22.3 (11.7–
50.5) nmol L)1 vs. 13.8 (7.0–24.5) nmol L)1 and 40.1 (15.8–
68.4) nmol L)1 respectively P < 0.05], whereas no difference
was found in vitamin B12 levels. Tissue factor and TFPI levels
were higher and respectively lower in Fabry patients than
controls [TF: 152 (46–274) pg mL)1 vs. 107 (22–313) pg mL)1;
P ¼ 0.18; TFPI: 43.0 (35.0–60.0) ng mL)1 vs. 86.3 (38.2–
151.0) ng mL)1, P < 0.0001 (Fig. 1B)].
These results suggest that hyperhcy may contribute to the
cerebral ischemic events in Fabry patients. Hyperhcy may
contribute to the endothelial dysfunction, which has been
demonstrated in Fabry’s disease [8,9]. In cerebral blood vessels
of patients with Fabry’s disease, a chronic alteration of the
nitric oxide (NO) pathway has been demonstrated [8,10] and
this condition may be influenced by Hcy, which increases the
oxidative degradation of NO [11]. Low folate and vitamin B6
levels may be low due to inadequate dietary intake, malab-
sorption, increased utilization or to effects of drugs [12–14]. In
this study, gastrointestinal manifestations were reported in
three of four patients who suffered from cerebrovascular
events, but malabsorption may take place in the absence of
clinical signs.
In Fabry’s disease, extensive clinical heterogeneity has been
related to different genetic mutations, of which more than 110
variants have been described [1,15]. Interestingly, we observed
that, in one of the families investigated, the three out of six
patients affected by Fabry’s disease, who suffered from
cerebrovascular ischemic events, were found to be hyperhcy,
suggesting the possible role of hyperhcy as mechanism
involved in increasing the risk of occurrence of cerebrovas-
cular events.
In this study, TFPI levels have been found to be low in all
the patients so suggesting a diffuse endothelial alterations
associated to the disease per se. Tissue factor pathway
inhibitor plays a primary role in regulating TF-induced
coagulation and significantly contributes to the anticoagulant
properties of the endothelium [16]. Tissue factor pathway
inhibitor decrease has been reported in conditions in which
blood clotting activation occurs [17]. Low levels of plasma
TFPI in Fabry’s disease may be attributed to the endothelial
dysfunction and/or consumption of the endothelial cell-
associated TFPI owing to the proinflammatory and proco-
agulant profile of the Fabry patients. TF may have a role in
determining the procoagulant profile to which other mecha-
nisms participate. In conclusion, the present study shows that
Hcy may have a role in the occurrence of cerebrovascular
events in Fabry patients and that reduced vitamin availability
is involved. The possible utility of checking for Hcy and
vitamin levels, in particular in the presence of gastrointestinal
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Fig. 1. Homocysteine plasma levels (1A) and TFPI plasma levels (1B) in Fabry’s disease patients.
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events, and the opportunity of vitamin administration
deserves confirmation in a larger group of patients with
Fabry’s disease.
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Further evidence that fibrillar collagen is unable to promote
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Platelet activation by collagen involves multiple receptors
including glycoprotein (GP)VI and the integrin a2b1 as
primary receptors, secondary agonists such as released ADP
acting on both P2Y1 and P2Y12 receptors and thromboxane
A2 (TXA2) activating Tp receptor. Intracellularly, PLCc2
downstream of GPVI, as well as the Gq and G13 a-subunits of
the heterotrimeric G-proteins have been demonstrated to be
key signaling elements during platelet activation by collagen.
We recently have shown that simultaneous inhibition of
TXA2 formation by aspirin and blockade of the P2Y1
receptor by gene targeting or using a selective P2Y1 antagonist
resulted in complete loss of shape change in platelets exposed
to a high concentration (100 lg mL)1) of fibrillar collagen [1].
Scanning electron microscopic (SEM) analysis provided clear
images of platelets in direct contact with collagen fibers that
had not undergone shape change and showed a typical resting
discoid ultrastructure. These data led us to propose that the
P2Y1 receptor plays a key role in collagen-induced platelet
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